Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference
September 09 2021 - 8:00AM
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of innovative, disease-modifying therapies for neurodegenerative
diseases, today announced that Richard Peters, M.D., Ph.D.,
President and Chief Executive Officer, will present at the H.C.
Wainwright 23rd Global Investment Conference.
The presentation will be available on-demand via the conference
portal and through the Company's website
at www.yumanity.com/events beginning at 7 a.m. EDT,
September 13.
About Yumanity TherapeuticsYumanity
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to accelerating the revolution in the treatment of
neurodegenerative diseases through its scientific foundation and
drug discovery platform. The Company’s most advanced product
candidate, YTX-7739, is currently in Phase 1 clinical development
for Parkinson’s disease. Yumanity’s drug discovery platform enables
the Company to rapidly screen for potential disease-modifying
therapies by overcoming the toxicity of misfolded proteins
associated with neurogenerative diseases. Yumanity’s pipeline
consists of additional programs focused on Lewy body dementia,
multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou
Gehrig’s disease), frontotemporal lobar dementia (FTLD), and
Alzheimer’s disease. For more information, please
visit www.yumanity.com.
Investors:Burns McClellan, Inc.Lee
Rothlroth@burnsmc.com(212) 213-0006
Media:Burns McClellan, Inc.Robert Flamm, Ph.D.
/ Harrison Wongrflamm@burnsmc.com / hwong@burnsmc.com (212)
213-0006 ext. 364 / 316
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jul 2023 to Jul 2024